Genome Engineering Market Size, Share, and Trends - Global Forecast 2026-2032 | CRISPR Commercialization and AI Innovation Propel 16.17% CAGR Toward USD 24.24 Billion
Dublin, Nov. 19, 2026 (GLOBE NEWSWIRE) -- "Genome Engineering Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering.
The genome engineering market research provides a comprehensive assessment of technologies, applications, competitive dynamics, and geographic opportunities shaping this rapidly expanding industry. Valued at a projected USD 9.83 billion in 2026, the market is expected to grow at a CAGR of 16.17% to reach USD 24.24 billion by 2032.
Market Overview
Genome engineering is advancing from a research-focused discipline into a commercially validated foundation for precision medicine, biomanufacturing, agriculture, and synthetic biology. Key technologies include CRISPR-Cas systems, base editing, prime editing, zinc finger nucleases, TALENs, and viral and non-viral delivery platforms.
Regulatory approvals have accelerated commercial momentum. The United Kingdom authorized the first CRISPR-based therapy in November 2023, followed by the United States in December 2023 for sickle cell disease. These milestones are increasing strategic interest across oncology, rare diseases, infectious disease research, crop development, and industrial biotechnology.
Transformative Market Shifts
The market is being reshaped by programmable nucleases, high-throughput sequencing, improved delivery systems, automation, and cloud-enabled computational biology. CRISPR-Cas9 remains widely adopted, while base and prime editing are attracting interest for their potential to achieve precise changes without double-strand DNA breaks.
Demand is shifting from standalone tools toward integrated platforms encompassing guide RNA design, off-target analysis, cell engineering, analytical validation, GMP readiness, and regulatory documentation. This analysis supports strategic planning by identifying the capabilities most likely to influence platform selection, partnerships, and long-term competitive positioning.
Artificial Intelligence in Genome Engineering
Artificial intelligence is accelerating target discovery, guide RNA selection, protein engineering, enzyme development, delivery-vector optimization, and off-target risk prediction. Models trained on genomic, transcriptomic, proteomic, and clinical data can reduce experimental cycles and improve edit prioritization.
Resources such as the AlphaFold Protein Structure Database demonstrate the value of broad access to predicted protein structures. As AI adoption expands, transparent validation, responsible data governance, and reproducibility will become increasingly important.
Regional and Economic Group Insights
Country-level comparisons offer practical guidance for evaluating market-entry options, regional partnerships, regulatory exposure, and investment priorities.
Strategic Priorities for Industry Leaders
These insights enable decision-makers to identify high-potential applications, mitigate development risks, and prioritize investments aligned with clinical and commercial readiness.
Key Takeaways from This Report
Key Attributes:
Key Topics Covered:
1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter's Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Genome Engineering Market, by Offering
7.1. Introduction
7.2. Instruments
7.2.1. Electroporation Systems
7.2.2. Microinjection Systems
7.3. Reagents & Consumables
7.3.1. Delivery Reagents
7.3.2. Kits & Enzymes
7.4. Software
7.4.1. Data Analysis
7.4.2. Design
7.5. Services
7.5.1. Screening
7.5.2. Assay Development
8. Genome Engineering Market, by Technology
8.1. Introduction
8.2. CRISPR Systems
8.2.1. CRISPR/Cas12
8.2.2. CRISPR/Cas9
8.3. Meganucleases
8.4. Transcription Control
9. Genome Engineering Market, by Delivery Method
9.1. Introduction
9.2. Ex-vivo
9.3. In-vivo
10. Genome Engineering Market, by Application
10.1. Introduction
10.2. Genetic Engineering
10.3. Clinical Therapeutics
10.4. Research & Discovery
11. Genome Engineering Market, by End User
11.1. Introduction
11.2. Academic & Research Institutes
11.3. Contract Research Organizations
11.4. Pharmaceutical & Biotechnology Companies
12. Genome Engineering Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Genome Engineering Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Genome Engineering Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. AgBiome, Inc.
16.2. Agilent Technologies, Inc.
16.3. BASF SE
16.4. Bayer AG
16.5. Beam Therapeutics
16.6. Bio-Rad Laboratories, Inc.
16.7. Charles River Laboratories Inc.
16.8. Cibus Inc.
16.9. Clinisys, Inc.
16.10. Corteva Agriscience
16.11. Creative Biogene
16.12. CRISPR Therapeutics AG
16.13. Danaher Corporation
16.14. GenScript Biotech Corporation
16.15. Groupe Limagrain Holding
16.16. Intellia Therapeutics, Inc.
16.17. Lonza Group AG
16.18. Merck KGaA
16.19. New England Biolabs
16.20. QIAGEN N.V.
16.21. Revvity Inc.
16.22. Synthego Holdings LLC
16.23. Takara Bio Inc.
16.24. Thermo Fisher Scientific Inc.
16.25. Twist Bioscience
17. Key Experts
List of Figures [21]
List of Tables [369]
For more information about this report visit https://www.researchandmarkets.com/r/q4sr7m
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.